Literature DB >> 16397841

TGF-beta/Smad signaling in the injured liver.

K Breitkopf1, P Godoy, L Ciuclan, M V Singer, S Dooley.   

Abstract

TGF-beta, acting both directly and indirectly, represents a central mediator of fibrogenic remodeling processes in the liver. Besides hepatic stellate cells (HSCs), which are induced by TGF-beta to transdifferentiate to myofibroblasts and to produce extracellular matrix, hepatocytes are also strongly responsive for this cytokine, which induces apoptosis during fibrogenesis and provides growth control in regeneration processes. Based on this, TGF-beta-mediated hepatic responses to injury are the result of a complex interplay between the different liver cell types. In this review we summarize the knowledge about TGF-beta signal transduction in HSCs with special impact on Smad pathways. We further describe a molecular cross-talk between profibrogenic TGF-beta and antifibrogenic IFN-gamma signaling in liver cells. Finally, we introduce hepatocyte plasticity and epithelial-to-mesenchymal transition in the liver, which is well established in tumorigenesis, as a potential feature of fibrogenesis and highlight possible action points of TGF-beta in these contexts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16397841     DOI: 10.1055/s-2005-858989

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  70 in total

1.  Osteopontin contributes to TGF-β1 mediated hepatic stellate cell activation.

Authors:  Xiao Xiao; Yi Gang; Yong Gu; Lina Zhao; Jindong Chu; Jinfeng Zhou; Xiqiang Cai; Hui Zhang; Li Xu; Yongzhan Nie; Kaichun Wu; Zhiguo Liu; Daiming Fan
Journal:  Dig Dis Sci       Date:  2012-06-04       Impact factor: 3.199

2.  Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C.

Authors:  R K Gieseler; G Marquitan; M Schlattjan; J-P Sowa; L P Bechmann; J Timm; M Roggendorf; G Gerken; S L Friedman; A Canbay
Journal:  J Viral Hepat       Date:  2010-08-15       Impact factor: 3.728

3.  Schistosoma japonicum protein SjP40 inhibits TGF-β1-induced activation of hepatic stellate cells.

Authors:  Xiaolei Sun; Lingbo Zhang; Jianxin Wang; Jinling Chen; Dandan Zhu; Pei Shen; Xue He; Jing Pan; Wenxia Peng; Yinong Duan
Journal:  Parasitol Res       Date:  2015-08-14       Impact factor: 2.289

Review 4.  Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors:  Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

Review 5.  Mechanisms of hepatic fibrogenesis.

Authors:  Ursula E Lee; Scott L Friedman
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

6.  Gα12 overexpression induced by miR-16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells.

Authors:  Kyu Min Kim; Chang Yeob Han; Ji Young Kim; Sam Seok Cho; Yun Seok Kim; Ja Hyun Koo; Jung Min Lee; Sung Chul Lim; Keon Wook Kang; Jae-Sung Kim; Se Jin Hwang; Sung Hwan Ki; Sang Geon Kim
Journal:  J Hepatol       Date:  2018-01-02       Impact factor: 25.083

7.  Glucocorticoids Have Opposing Effects on Liver Fibrosis in Hepatic Stellate and Immune Cells.

Authors:  Kang Ho Kim; Jae Man Lee; Ying Zhou; Sanjiv Harpavat; David D Moore
Journal:  Mol Endocrinol       Date:  2016-06-29

Review 8.  Mechanisms of hepatic fibrogenesis.

Authors:  Scott L Friedman
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

9.  Thyroid hormones inhibit TGF-β signaling and attenuate fibrotic responses.

Authors:  Elvira Alonso-Merino; Rosa Martín Orozco; Lidia Ruíz-Llorente; Olaia A Martínez-Iglesias; Juan Pedro Velasco-Martín; Ana Montero-Pedrazuela; Luisa Fanjul-Rodríguez; Constanza Contreras-Jurado; Javier Regadera; Ana Aranda
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 11.205

Review 10.  Advances in antifibrotic therapy.

Authors:  Zahra Ghiassi-Nejad; Scott L Friedman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.